414 related articles for article (PubMed ID: 37234776)
1. Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions.
Liu J; Piranlioglu R; Ye F; Shu K; Lei T; Nakashima H
Front Cell Infect Microbiol; 2023; 13():1141034. PubMed ID: 37234776
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.
Blitz SE; Kappel AD; Gessler FA; Klinger NV; Arnaout O; Lu Y; Peruzzi PP; Smith TR; Chiocca EA; Friedman GK; Bernstock JD
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163730
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: how to break a vicious cycle.
Wurdinger T; Deumelandt K; van der Vliet HJ; Wesseling P; de Gruijl TD
Biochim Biophys Acta; 2014 Dec; 1846(2):560-75. PubMed ID: 25453365
[TBL] [Abstract][Full Text] [Related]
4. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells.
Chang AL; Miska J; Wainwright DA; Dey M; Rivetta CV; Yu D; Kanojia D; Pituch KC; Qiao J; Pytel P; Han Y; Wu M; Zhang L; Horbinski CM; Ahmed AU; Lesniak MS
Cancer Res; 2016 Oct; 76(19):5671-5682. PubMed ID: 27530322
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Virotherapy in Glioma Tumors.
Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
[TBL] [Abstract][Full Text] [Related]
6. CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy.
Pant A; Hwa-Lin Bergsneider B; Srivastava S; Kim T; Jain A; Bom S; Shah P; Kannapadi N; Patel K; Choi J; Cho KB; Verma R; Yu-Ju Wu C; Brem H; Tyler B; Pardoll DM; Jackson C; Lim M
Oncoimmunology; 2024; 13(1):2338965. PubMed ID: 38590799
[TBL] [Abstract][Full Text] [Related]
7. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.
Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X
Front Immunol; 2020; 11():737. PubMed ID: 32391020
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
Suryawanshi YR; Schulze AJ
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking.
Tan Z; Chiu MS; Yue M; Kwok HY; Tse MH; Wen Y; Chen B; Yang D; Zhou D; Song YQ; Man K; Chen Z
J Leukoc Biol; 2024 Mar; 115(4):633-646. PubMed ID: 38066571
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
15. Role of myeloid cells in the immunosuppressive microenvironment in gliomas.
Locarno CV; Simonelli M; Carenza C; Capucetti A; Stanzani E; Lorenzi E; Persico P; Della Bella S; Passoni L; Mavilio D; Bonecchi R; Locati M; Savino B
Immunobiology; 2020 Jan; 225(1):151853. PubMed ID: 31703822
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virus Ad-TD-nsIL-12 inhibits glioma growth and reprograms the tumor immune microenvironment.
Li S; Guo Y; Ning W; Chen Y; Xu J; Zhao C; Wang J; Qu Y; Zhang M; Wang P; Wang Y; Wang S; Zhang H
Life Sci; 2024 Jan; 336():122254. PubMed ID: 37977355
[TBL] [Abstract][Full Text] [Related]
17. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
Hofman L; Lawler SE; Lamfers MLM
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies.
Salemizadeh Parizi M; Salemizadeh Parizi F; Abdolhosseini S; Vanaei S; Manzouri A; Ebrahimzadeh F
Inflammopharmacology; 2021 Dec; 29(6):1613-1624. PubMed ID: 34613567
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
20. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.
Pang L; Khan F; Heimberger AB; Chen P
Trends Cancer; 2022 Oct; 8(10):839-854. PubMed ID: 35624002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
